Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
A D'Avola, K Kluckova, AJ Finch… - OncoTargets and …, 2023 - Taylor & Francis
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
[HTML][HTML] Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
A D'Avola, K Kluckova, AJ Finch… - OncoTargets and …, 2023 - ncbi.nlm.nih.gov
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.
A D'Avola, K Kluckova, AJ Finch… - Oncotargets and …, 2023 - europepmc.org
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
A D'Avola, K Kluckova, AJ Finch… - OncoTargets and …, 2023 - dovepress.com
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
[PDF][PDF] Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
A D'Avola, K Kluckova, AJ Finch… - OncoTargets and …, 2023 - scienceopen.com
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
[PDF][PDF] Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
A D'Avola, K Kluckova, AJ Finch… - OncoTargets and …, 2023 - pdfs.semanticscholar.org
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
A D'Avola, K Kluckova, AJ Finch… - OncoTargets and …, 2023 - pubmed.ncbi.nlm.nih.gov
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.
A D'Avola, K Kluckova, AJ Finch… - OncoTargets & …, 2023 - search.ebscohost.com
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.
A D'Avola, K Kluckova, AJ Finch… - OncoTargets and Therapy, 2023 - go.gale.com
MYC can be considered to be one of the most pressing and important targets for the
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
development of novel anti-cancer therapies. This is due to its frequent dysregulation in …
[引用][C] Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
A D'Avola, K Kluckova, AJ Finch… - ONCOTARGETS AND …, 2023 - qmro.qmul.ac.uk
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers Toggle navigation Login
Toggle navigation Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers QMRO …
Toggle navigation Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers QMRO …